Google
Trusted Resources: News & Events
Latest announcements and gatherings
First systemic evidence for safety of tPA in stroke patients with sickle cell disease
In the largest report on acute stroke in sickle cell disease to date, researchers at the Medical University of South Carolina and elsewhere provide the first systemic evidence for the safe use of tPA in stroke patients with sickle cell disease.
Adult patients with sickle cell disease (SCD) who experience a stroke caused by a clot (i.e., ischemic strokes or IS) can be treated safely with tissue plasminogen activator (tPA) if they qualify, report investigators at the Medical University of South Carolina (MUSC) and elsewhere in the March 2017 issue of Stroke.
+myBinderRelated Content
-
ASH launches sickle cell disease clinical trials network to accelerate therapy developmentASH launched a clinical trials network d...
-
Stuart H. Orkin, MDDr. Orkin is David G. Nathan Distinguish...
-
FDA Approves Hydroxyurea Tablets for Pediatric Patients With Sickle Cell AnemiaThe US Food and Drug Administration (FDA...
-
Gene therapy targets sickle-cell diseaseElliott Vichinsky estimates that at leas...
-
Sickle Cell Disease: Managing PainCurrently, sickle cell disease has no wi...
-
Cognitive Function may be Affected in Adults With Sickle Cell Disease, Study SuggestsAdults with sickle cell disease score wo...
-
Comparing Sickle Cell Disease Acute Pain Management in the Pediatric and Adult Emergency DepartmentBackground: Vasoocclusive pain leading ...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.